Introduction
Recent studies suggest that short-acting calcium antagonists increase coronary artery morbidity and mortality, and non-cardiovascular complications (1, 2) . In the Sixth Report of the Joint National Committee (JNC VI) of USA (3), immediate-release nifedipine was shown to precipitate ischemic events and, in large doses, may increase coronary mortality in patients who have had myocardial infarction. The report stated that this agent should be used only with great caution, if at all, and long-acting calcium antagonists were recommended. The reflex increase in sympathetic activity induced by short-acting calcium antagonists provoked the observed proischemic, negative inotropic, and arrhythmogenic effects, triggering cardiac events and death, especially in coronary artery disease a safe alternative, avoiding this sympathetic activation (5) . Both short-acting and intermediate-acting calcium antagonists have trough-peak blood pressure (BP) response ratios of less than the 50% recommended by the U.S. Food and Drug Administration (FDA), while that of long-acting agents is over 60% (6) .
Recently, Holter ECG has been used for the monitoring of spontaneous heart rate variability (HRV) to assess diurnal sympathetic and parasympathetic cardiac tone (7, 8) . Also, instead of the short-acting or intermediateacting forms, long-acting calcium antagonist is being used more commonly. We studied the benefit of switching to the long-acting form (benidipine) in hypertensive patients with CAD, in whom BP has been well-controlled by intermediate-acting calcium antagonist (nifedipine) for a long period. We measured diurnal BP changes and cardiac autonomic activity assessed by HRV.
Patients and Methods

Patients
We studied 25 hypertensive outpatients with CAD, who had been treated with nifedipine for at least 3 mo before entering this study. They all had had chest pain and had been diagnosed by exercise stress test (both exercise electrocardiography and stress myocardial perfusion imaging with 201thallium). Coronary arteriography was performed in 22 patients. The clinical characteristics of the patients who entered the study are shown in Ambulatory BP Monitoring and HRV Assessment
Noninvasive ambulatory monitoring of BP and RR intervals was carried out on a weekday with an automatic ambulatory BP monitor (TM-2420, A&D Co., Inc., Tokyo, Japan), which was equipped with ambulatory 24-h ECG monitoring. The accuracy of this device was previously validated (9) . The ambulatory BP data used on that day were obtained by the oscillometric method. Both BP and heart rate (HR) were measured every 30 min for 24 h. The RR interval data were analyzed using the fastFourier transform method. Power spectral densities of rhythmic oscillations over a frequency range of 0.4 Hz or less were obtained during all beats every 5 min to analyze the low-frequency power (LF: 0.04 to 0.15 Hz) as an index of both sympathetic nervous and parasympathetic nervous system activity, the high-frequency power (HF: 0.15 to 0.40 Hz) as an index of parasympathetic nervous system activity (10, I1), and the LF/HF ratio as an indirect index of sympathetic nervous activity (10, I1).
Each subject recorded an activities journal in which he or she noted information about the exact times of going to bed and waking up, to determine the daytime and nighttime periods. The nighttime values for HRV parameters (LF, HF, and the LF/HF ratio) and BP parameters were calculated as the mean value from the time the patient went to bed until the time of awakening, and the daytime values were calculated as the mean values during the remaining period. The morning period was defined as the average 2-h period after arising from bed, as stated in each patient ' Figure 1 shows the diurnal BP and HR variation in the two phases. There were no significant differences between the nifedipine phase and the benidipine phase in the office, 24-h, daytime, and nighttime BP or HR (Table 2 ). There were also no significant differences between the two phases in the morning BP and HR, or in the night lowest BP and HR, and there were no differences in BP or HR between daytime and nighttime or the diurnal BP variation of the baseline night-day ratios of BP and HR. Furthermore, there were no significant differences between the nifedipine phase and the benidipine phase in the 24-h, daytime and nighttime BP variation (SD of 24-h, day and night BP) ( Table 3 ). Figure 2 shows the mean (± SE) BP and HR changes after administration (from 2 to 4 h) of each drug in the morning. There were no significant differences in SBP, DBP, and HR levels before and after each drug. There were also no differences in the mean changes in BP and HR levels between the nifedipine and benidipine phases. As for evening administration of nifedipine, SBP and DBP after administration were lower than those before (before administration: SBP 137.6 ± 2.9 mmHg, DBP 87.1 ± 1.7 mmHg; after administration: SBP 118.6 ± 2.7 mmHg, DBP 72.5 ± 1.8 mmHg:
p < 0.01). However, these changes were also found in the same evening period during the benidipine phase.
Diurnal Heart Rate Variability Figure 3 and Table 4 show the results of power spectral analysis of HRV during the two phases. There were no significant differences between nifedipine and benidipine for LF or HF and LF/HF ratios, 24-h, daytime and nighttime periods, the morning periods, the night-lowest periods, and the differences between daytime and nighttime. Figure 4 shows the changes in LF, HF, and LF/HF ratios after morning administration of each drug. There and heart rate during were no significant differences between pre-and postadministration of each drug, except in the LF component of nifedipine. There were no differences in the mean change of each HRV parameter between nifedipine and benidipine (data not shown). As for administration of nifedipine in the evening, there were no significant differences in LF and HF components between before and after. The LF/HF ratio after administration was lower than that before (before administration: LF/HF ratio 2.5 ± 1.1; after administration: LF/HF 1.7 ± 1.1: p < 0.05), howev- er, there were no differences in the mean changes of the evening HRV parameters between nifedipine and benidipine (data not shown).
Discussion
In the present study, we demonstrated that administration of the intermediate-acting agent nifedipine and of the long-acting agent benidipine reduced the mean 24-h BP level to the same extent. Furthermore, we found that the nocturnal and morning BP reductions caused by twice daily administration of nifedipine was equivalent. There were also no significant differences between nifedipine and benidipine phases in BP variability (SD of 24-h, day and night BP) and diurnal sympatho-vagal balance assessed by HRV. Bigger et al. (12) found that after myocardial infarction, patients had smaller LF and HF components compared to the control group. Hayano et al. (13) reported that coronary artery disease was associated with vagal dominant impairment in autonomic cardiac function and that reduction in vagal cardiac function correlates with angiographic severity. The HRV parameters were related neither to previous history of myocardial infarction nor to stenosis of any specific artery (data not shown).
We found no significant differences between the intermediate-acting calcium antagonist and the long-acting calcium antagonist in diurnal autonomic nervous activity when assessed by HRV.
A previous report (14) disclosed that the long-acting agent amlodipine did not induce an increase in sympathetic nerve activity assessed by HRV during ECG monitoring, and that of intermediate-acting (slow-releasing) nifedipine induced a milder reflex sympathetic activation than did short-acting nifedipine. There is another report showing that some calcium channel blockers have shorter ultradian periodicity of variation in SBP and DBP than other antihypertensive agents (15). Previously, we found that diurnal autonomic nervous system activity is related to diurnal BP variation (8) . The reason for the lack of difference in HRV components between the two phases in our study might be due to a lack of significant difference in BP variability.
Rapid BP reduction induced by acute vasodilatation due to short-acting nifedipine elicits activation of the sympathetic nervous system and an adverse neurohormoral response. This sympathetic nervous system activation mechanism acts behind the observed proischemic, negative inotropic, and arrythmogenic effects (1) . In this study, BP, HR, and HRV parameters (HF and LF/HF ratio) from 2 to 4 h after nifedipine administration (probably the most effective period of the intermediate agent)
were not different from those before administration. There was a significant difference in the LF component. The LF power acts as an index of both sympathetic nervous and parasympathetic nervous activity (10) . Since there was no significant difference in the LF/HF ratio, we could not conclude that the sympatho-vagal axis shifted to sympathetic activation after intermediate-acting nifedipine administration. In the administration of nifedipine in the evening, we found significant decreases in SBP, DBP and LF/HF. However, when compared with the same evening period of benidipine phase, the changes were not significantly different. Thus, these changes might be due not to the effect of the drug, but to behavioral changes in the evening (position, activity, etc). These behavioral factors are the determinants of daytime BP and diurnal BP variation (16).
A limitation of our study is that it is not a randomized 
